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Abstract
Quinazoline-basedA1-adrenoceptor antagonists, in par-
ticular doxazosin and terazosin, are suggested to dis-
play antineoplastic activity against prostate cancers.
However, there are few studies elucidating the effect
of prazosin. In this study, prazosin displayed antipro-
liferative activity superior to that of other A1-blockers,
including doxazosin, terazosin, tamsulosin, and phen-
tolamine. Prazosin induced G2 checkpoint arrest and
subsequent apoptosis in prostate cancer PC-3, DU-145,
and LNCaP cells. In p53-null PC-3 cells, prazosin in-
duced an increase in DNA strand breaks and ATM/ATR
checkpoint pathways, leading to the activation of down-
stream signaling cascades, including Cdc25c phos-
phorylation at Ser216, nuclear export of Cdc25c, and
cyclin-dependent kinase (Cdk) 1 phosphorylation at
Tyr15. The data, together with sustained elevated cyclin
A levels (other than cyclin B1 levels), suggested that
Cdk1 activity was inactivated by prazosin. Moreover,
prazosin triggered mitochondria-mediated and caspase-
executed apoptotic pathways in PC-3 cells. The oral ad-
ministration of prazosin significantly reduced tumormass
in PC-3–derived cancer xenografts in nude mice. In sum-
mary, we suggest that prazosin is a potential antitumor
agent that induces cell apoptosis through the induction
of DNA damage stress, leading to Cdk1 inactivation
and G2 checkpoint arrest. Subsequently, mitochondria-
mediated caspase cascades are triggered to induce
apoptosis in PC-3 cells.
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Introduction
A number of discoveries have identified the molecular
mechanism of apoptosis and have clarified its contribution
to therapeutic outcome, in particular cancer chemothera-
peutics. In the prostate, androgen deprivation substantially
causes apoptosis in androgen-dependent prostate cancer
cells, but not in androgen-independent tumor epithelial cells
[1]. However, these nonsusceptible tumor cells undergo apop-
tosis with numerous chemotherapeutic agents and irradiation
[2,3]. Recently, many apoptotic strategies based on different mo-
lecular mechanisms have been proposed to deal with androgen-
independent prostate cancer cells. The death receptor pathway
is one of the targets in apoptotic strategies. Several agents have
been identified as triggering apoptosis in androgen-independent
prostate cancer cells through this extrinsic apoptosis pathway,
for example, valproic acid through overexpression of Fas and
Fas ligand [4], coral prostanoids through Fas clustering [5], and
flavonoids through induction of death receptor 5 expression [6].
Recently, tubulin has been one of the most widely studied
targets. A variety of natural components and synthetic com-
pounds have been reported to bind to tubulin, causing cell-cycle
arrest and apoptosis in many types of tumor cells, including
androgen-independent prostate cancer cells [7,8]. Moreover,
mitochondria-involved apoptotic signaling always mutually inter-
acts with the above pathways and explains most of the apoptotic
mechanisms of chemotherapeutic agents [9–11].
a1-Adrenoceptor antagonists are used as first-line medi-
cal treatment for patients with benign prostatic hyperplasia–
related lower urinary tract symptoms. Recently, the effect of
a1-adrenoceptor antagonists on the apoptosis of both androgen-
dependent and androgen-independent prostate cancer cells
has been investigated. Interestingly, several lines of evidence
suggest that apoptotic effect is independent of the blockade of
a1-adrenoceptors. One of the evidences suggests that apop-
totic effect is specific for quinazoline-based antagonists (e.g.,
doxazosin and terazosin) other than sulfonamide derivatives
(e.g., tamsulosin) [12,13]. Doxazosin is the most widely inves-
tigated a1-adrenoceptor antagonist. Several signaling path-
ways have been identified to explain doxazosin-induced anoikis
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and cell apoptosis, namely, 1) activation of transforming
growth factor-b and InB pathways [14]; 2) inhibition of protein
kinase B/Akt activation [15]; 3) induction of death receptor–
mediated apoptosis [16]; 4) increase in Bax expression [17];
and 5) reduction in focal adhesion kinase [18].
There is another implication behind the discovery of
doxazosin in anticancer study—‘‘old drugs with new indica-
tion.’’ Two advantages in this strategy are shortening of dis-
covery time and reduction of discovery cost. Based on this
strategy, we have performed large-scale anticancer screen-
ing tests in clinically used drugs with sulforhodamine B (SRB)
assay, which is regularly used in the US National Cancer In-
stitute’s disease-oriented anticancer drug discovery screen.
As expected, the class of a1-adrenoceptor antagonists was
able to display anticancer activity in numerous prostate can-
cer cell lines, including PC-3, DU-145, and LNCaP. Interest-
ingly, prazosin (a quinazoline derivative) was more potent
than doxazosin in these cancer cell lines. After the investi-
gation of mechanism, the data showed that prazosin induced
apoptotic cell death through pathways distinct from those
caused by doxazosin. Furthermore, not only quinazoline-
based derivatives but also imidazoline-based derivatives
(i.e., phentolamine) displayed anticancer activity. In this study,
anticancer mechanism and in vivo efficacy have been deter-
mined to demonstrate the anticancer potential of prazosin.
Materials and Methods
Materials
RPMI 1640 medium, fetal bovine serum (FBS), penicillin,
streptomycin, and all other tissue culture regents were ob-
tained from GIBCO/BRL Life Technologies (Grand Island,
NY). Antibodies toGRP78 (glucose-regulated protein 78), Bcl-2,
Mcl-1, Bak, Bax, poly(ADP-ribose)polymerase (PARP), cy-
clins A and B1, cyclin-dependent kinase (Cdk) 1, Cdk2, Cdc25c,
and anti-mouse and anti-rabbit IgG were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies to p53,
phosphor-p53Ser15, p21Cip1/Waf1, p27Kip1, caspase-9, caspase-8,
caspase-7, phospho-Cdk1Tyr15, phospho-Cdk1Thr161, andBid
were obtained fromCell Signaling Technologies (Boston, MA).
Antibodies to DADD153 and caspase-3 were obtained from
Imgenex (San Diego, CA). Antibody to a-tubulin was obtained
from Serotec Products (Beverly, MA). Antibody to m-calpain
was obtained from BioVision (Mountain View, CA). Terminal
uridine deoxynucleotidyl transferase dUTP nick end label-
ing (TUNEL) apoptosis detection kits were obtained from
Promega (Madison, WI). Hoechst 33342, etoposide, EDTA,
leupeptin, dithiothreitol, phenylmethylsulfonylfluoride, SRB,
propidium iodide (PI), and all of the other chemical reagents
were obtained from Sigma (St. Louis, MO).
Cell Culture
The NCI/ADR-RES cell line was obtained from the DTP
Human Tumor Cell Line Screen (Developmental Therapeu-
tics Program, National Cancer Institute). The other cancer
cell lines were obtained from the American Type Culture Col-
lection (Rockville, MD). Human cancer cells were cultured in
RPMI 1640 medium with 10% FBS (vol/vol) and penicillin
(100 U/ml)/streptomycin (100 mg/ml). Cultures were main-
tained in a humidified incubator at 37jC in 5% CO2/95% air.
SRB Assays
Cells were seeded on 96-well plates in a medium with 5%
FBS. After 24 hours, cells were fixed with 10% trichloroacetic
acid to represent the cell population at the time of drug ad-
dition (T0). After additional incubation of DMSO or drugs for
48 hours, the cells were fixed with 10% trichloroacetic acid,
and SRB at 0.4% (wt/vol) in 1% acetic acid was added to
stain cells. Unbound SRB was washed out by 1% acetic acid,
and SRB-bound cells were solubilized with 10 mM Trizma
base. Absorbance was read at a wavelength of 515 nm. Us-
ing the following absorbance measurements, such as time
zero (T0), control growth (C), and cell growth in the presence
of the drug (Tx), the percentage of growth was calculated at
each of the compound concentrations levels. Percent growth
inhibition was calculated as: 100  [(Tx  T0)/(C  T0)] 
100. Fifty percent growth inhibition (IC50) is determined at the
drug concentration that results in a 50% reduction in total
protein increase in control cells during compound incubation.
In Situ Labeling of Apoptotic Cells
In situ detection of apoptotic cells was performed using
Hoechst 33342 staining and TUNEL apoptosis detection
methods. After a 36-hour treatment with or without prazosin
(30 mM), the cells were washed twice with PBS, stained with
Hoechst 33342 (1 mg/ml) for 15 minutes at 37jC, and fixed
for 15 minutes with 4% paraformaldehyde. They were ex-
amined under a confocal laser microscopic system (Leica
TCS SP2; Leica Microsystems, Mannheim, Germany). The
TUNEL method identifies apoptotic cells using TdT to transfer
biotin dUTP to the free 3V-OH of cleaved DNA. Biotin-labeled
cleavage siteswere then visualized by reactionwith fluorescein-
conjugated avidin. Cells were treated with or without prazosin.
Then the cells were washed, fixed, and stained for apoptotic
detection, in accordancewith the protocol provided byPromega.
Photomicrographs were obtained with a fluorescence micro-
scope (Nikon, Tokyo, Japan).
FACScan Flow Cytometric Assay
After the treatment of cells with vehicle (0.1% DMSO) or
compound for the indicated time courses, the cells were
harvested by trypsinization, fixed with 70% (vol/vol) alcohol
at 4jC for 30 minutes, and washed with PBS. After centrifu-
gation, the cells were incubated in 0.1 M phosphate–citric
acid buffer (0.2 M NaHPO4 and 0.1 M citric acid, pH 7.8) for
30 minutes at room temperature. Then the cells were centri-
fuged and resuspended with 0.5 ml of PI solution contain-
ing Triton X-100 (0.1% vol/vol), RNase (100 mg/ml), and PI
(80 mg/ml). DNA content was analyzed with FACScan and
CellQuest software (Becton Dickinson, Mountain View, CA).
Western Blot Analysis
After the indicated exposure time of cells to DMSO or the
indicated agent, cells were washed twice with ice-cold PBS
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and the reaction was terminated by the addition of 100 ml of
ice-cold lysis buffer (10 mM Tris–HCl pH 7.4, 150 mM NaCl,
1 mM EGTA, 1 mM phenylmethylsulfonylfluoride, 10 mg/ml
aprotinin, 10 mg/ml leupeptin, and 1% Triton X-100). For
Western blot analysis, the amount of proteins (40 mg) was
separated by electrophoresis into a 10% or a 15% polyacryl-
amide gel and transferred to a nitrocellulose membrane.
After an overnight incubation at 4jC in PBS/5% nonfat milk,
the membrane was washed with PBS/0.1% Tween 20 for
1 hour and immunoreacted with the indicated antibody for
2 hours at room temperature. After four washings with PBS/
0.1% Tween 20, the anti-mouse or anti-rabbit IgG (diluted
1:2000) was applied to the membranes for 1 hour at room
temperature. The membranes were washed with PBS/0.1%
Tween 20 for 1 hour, and signal detection was performed with
an enhanced chemiluminescence detection kit (Amersham,
Buckinghamshire, UK).
Comet Assay to Monitor the Integrity of Chromosomal DNA
Prazosin-treated or etoposide-treated cells (2  105;
30 minutes) were pelleted and resuspended in ice-cold PBS.
The resuspended cells were mixed with 1.5% low-melting-
point agarose. This mixture was loaded onto a fully frosted
slide that had been precoated with 0.7% agarose, and a cov-
erslip was then applied to the slide. The slides were sub-
merged in prechilled lysis solution (1% Triton X-100, 2.5 M
NaCl, and 10 mM EDTA, pH 10.5) for 1 hour at 4jC. After the
slides had been soaked with prechilled unwinding and elec-
trophoresis buffer (0.3 M NaOH and 1 mM EDTA) for 20 min-
utes, they were subjected to electrophoresis for 15 minutes
at 0.5 V/cm (20 mA). After electrophoresis, the slides were
stained with 1 Sybr Gold (Molecular Probes, Eugene, OR),
and nuclei images were visualized and captured at 400mag-
nification with an Axioplan 2 fluorescence microscope (Zeiss,
Tokyo, Japan) equippedwith a charge-coupled device camera
(Optronics, Goleta, CA). Hundreds of cells were scored to cal-
culate the overall percentage of Comet tail–positive cells.
In Vivo Antitumor Models
PC-3-derived cancer xenografts in nude mice were used
as an in vivomodel. The nude mice were subcutaneously in-
jected with PC-3 cells (107 cell/mouse). The tumors were
measured every 2 to 3 days. When the tumors had reached a
volume of 100 to 140 mm3, the mice were divided into three
groups (n = 7) and drug treatment was initiated. Prazosin
was suspended in 0.5% carboxymethyl cellulose (CMC).
Vehicle (0.5% CMC) or prazosin (3 and 10 mg/kg) was given
orally every day. The length (l ) and width (w ) of the tumor
were measured every 2 to 3 days, and tumor volume was
calculated as lw 2/2. The protocols of the in vivo study were
approved by the Animal Care and Use Committee at National
Taiwan University.
Data Analysis
The compound was dissolved in DMSO. The final con-
centration of DMSOwas 0.1% in cells. Data are presented as
the mean ± SEM of the indicated number of separate experi-
ments. Statistical analysis of data was performed with one-
way analysis of variance followed by Bonferroni t-test. P <
.05 was considered significant.
Results
Examination of the Anticancer Activities of Several
a1-Adrenoceptor Antagonists
The effect of several a1-adrenoceptor antagonists on cell
proliferation was evaluated in androgen-dependent (LNCaP)
and androgen-independent (PC-3 and DU-145) prostate
cancer cell lines. As demonstrated in Figure 1A, all of these
drugs inhibited cell growth in a dose-dependent manner. The
concentration of 50% inhibition on cell growth (IC50) was
obtained (Figure 1B). The data showed that prazosin was
most effective, with IC50 values of 11.1, 16.7, and 7.5 mM in
PC-3, DU-145, and LNCaP, respectively. The order of po-
tency was as follows: prazosin > doxazosin > phentolamine >
terazosin > tamsulosin. Interestingly, prazosin was two-fold
more potent than doxazosin, the most widely investigated
a1-adrenoceptor antagonist [12–18]. Cell morphology was
examined in PC-3 cells. The cells exhibited multinucleus
features and formation of apoptotic bodies after 18 and 24
hours of treatment with prazosin, respectively (Figure 1C).
The TUNEL reaction and Hoechst 33342 staining assays
showed that prazosin induced an increase in positive stain-
ing, suggesting cell apoptosis in response to prazosin action
(Figure 1D).
Detection of Cell-Cycle Progression and Regulators in
p53-Null PC-3
Flow cytometric analysis showed that doxazosin and
prazosin effectively induced an increase in sub-G1 popula-
tion (apoptosis; Figure 2A). Quantified data showed that pra-
zosin, but not doxazosin, induced a concentration-dependent
and time-dependent G2/M arrest of the cell cycle and sub-
sequent apoptosis (Figure 2, B and C). The data also dem-
onstrated a correlation between G2/M arrest and growth
inhibition (Figure 2B, solid curve) in response to prazosin-
mediated (other than doxazosin-mediated) effects. Accord-
ingly, several cell-cycle regulators were examined. Cyclin A
and its catalytic partner Cdk2 dominate S and G2 phases;
cyclin B1 and Cdk1 regulate cell-cycle progression from G2
to M phase. The data demonstrated that following a 6-hour
exposure to prazosin, cyclin A was upregulated and sustained
at a high level. In contrast, a short-term elevation, followed
by a decreased cyclin B level, was induced by prazosin (Fig-
ure 3A). These data were different from those by antimitotic
agents. In our data (not shown), both Taxol (Sigma, Louis,
MA) and vincristine (two tubulin-targeting agents) induced
mitotic arrest associated with upregulation of cyclin B1 ex-
pression. Furthermore, using monoclonal antibody MPM-2 to
recognize mitotic phosphoproteins, the MPM-2 expression
stimulated by prazosin (30 mM), Taxol (0.1 mM), and vincristine
(0.1 mM) for 24 hours was 88%, 240%, and 207%, respec-
tively, when compared with 100% of control, revealing that
prazosin did not increase MPM-2 expression. Collectively, it is
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suggested that prazosin induces G2 other than the mitotic
arrest of the cell cycle in PC-3.
To identify Cdk1 activity, the phosphorylation state of
Cdk1 was examined because Cdk1 phosphorylation at
Thr161 and dephosphorylation at Tyr15 are responsible for
the activation of Cdk1 [19]. As a result, prazosin induced a
time-dependent increase in Cdk1 phosphorylation at Tyr15,
but not at Thr161, indicating inhibition of Cdk1 activity (Fig-
ure 3B). Several lines of evidence suggest that dephosphor-
ylation of Cdk1 at Tyr15 is mainly achieved by the nuclear
phosphatase Cdc25c. Chk1 and Chk2 can phosphorylate
Cdc25c at Ser216, which subsequently binds to 14-3-3, lead-
ing to cytoplasmic sequestration of Cdc25c [20,21]. Our data
demonstrated that prazosin stimulated an increase in
Cdc25c phosphorylation at Ser216 and a subsequent de-
crease in nuclear Cdc25c (Figure 3B). The results may ex-
plain the accumulation of phosphorylation at Tyr15 and the
inactivation of Cdk1 in response to prazosin action.
Figure 1. Antineoplastic effect of a-adrenoceptor antagonists on several human prostate cancer cell lines. The compound, at the indicated concentration, was
added to cells for 48 hours. Then the cells were fixed and stained with SRB. After a series of washings, bound SRB was subsequently solubilized and absorbance
was read at a wavelength of 515 nm. Data are expressed as the mean ± SEM of four independent determinations (each in triplicate) (A). IC50 values were
calculated as described in the Materials and Methods section (B). PC-3 cells were treated with or without prazosin (30 M) for the indicated times. Cell morphology
was detected by microscopic examination (C). PC-3 cells were treated with or without prazosin (30 M) for 36 hours. Apoptosis was detected by TUNEL and
Hoechst 33342 reaction techniques (D). Scale bar, 20 m. *IC50 > 100 M.
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Figure 2. Effect of a-adrenoceptor antagonists on cell-cycle progression. Cells were treated with the indicated drug at various concentrations for 48 hours. Then the
cells were fixed and stained with PI to analyze DNA content by FACScan flow cytometric analysis. Data are representative of three independent experiments (A and
B). The inhibition of cell growth by doxazosin and prazosin using SRB assay (solid curves) is demonstrated. The data show that growth inhibition is correlated with
the population in G2/M phase in response to prazosin action, but not with PC-3 cells in response to doxazosin action (B). Prazosin (30 M)–mediated time-
dependent change in G2/M phase and sub-G1 population were detected by FACScan flow cytometric analysis in PC-3 cells. Data are expressed as the mean ±
SEM of three independent determinations. *P < .05 and **P < .01 compared with the respective controls (zero time) (C).
834 Anticancer Mechanism of Prazosin in Prostate Cancers Lin et al.
Neoplasia . Vol. 9, No. 10, 2007
Identification of Upstream Events Contributing to
Cell-Cycle Dysregulation
Caffeine, an inhibitor of ATM and ATR kinase activities,
was used to examine the role of ATM and ATR kinases. As
demonstrated in Figure 4A, caffeine was able to inhibit
prazosin-mediated G2 arrest and to restore the increased
G1 population of the cell cycle, suggesting the functional in-
volvement of ATM and/or ATR checkpoint pathways. Fur-
thermore, Comet assay showed that the exposure of PC-3
cells to prazosin (1 hour) induced a concentration-dependent
increase in DNA strand breaks; etoposide, a topoisomerase
II inhibitor, was used as a positive control (Figure 4B).
Determination of DNA Damage–Induced Apoptotic
Signaling Cascades
An important issue of DNA damage is that it not only
targets DNA but also causes stress in other cellular com-
ponents, leading to amplification of apoptosis. The mito-
chondria and endoplasmic reticulum are two susceptible
organelles [22,23]. To determine the role of endoplasmic
reticulum stress, several related proteins were examined.
However, prazosin neither stimulated the upregulation of
GRP78 and GADD153 (growth and DNA damage protein
153) nor induced the cleavage of m-calpain (Figure 5A).
Next, mitochondria-related events were examined. After a
12-hour treatment, prazosin induced the cleavage of Mcl-1
into several fragments (Figure 5B). It also triggered the
cleavage of Bad and Bid associated with the formation of
truncated fragments (Figure 5C). The data suggest that mi-
tochondria are the susceptible organelles for apoptotic reac-
tion in response to DNA damage stress.
Activation of caspases leads to the cleavage and activa-
tion/inactivation of many critical cellular substrates, including
the DNA repair enzyme PARP. To determine the caspases
committing prazosin-treated cells to apoptosis, the expres-
sions of several caspases were detected by Western immu-
noblotting. After treatment with prazosin, the cleavage of
PARP and caspases into catalytically active fragments was
clearly detected in a time-dependent manner, suggesting the
activation of these caspases (Figure 5D).
Prazosin Displays In Vivo Antitumor Efficacy
We subsequently carried out an in vivo study. The PC-3-
derived cancer xenografts in nude mice were used as an
Figure 3. Effect of prazosin on the expression of several cell-cycle regulators. (A and B) PC-3 cells were incubated in the absence or in the presence of prazosin
(30 M) for the indicated times. Then the cells were harvested and lysed for the detection of protein expression with the antibody by Western blot analysis. For
Western blot analysis, the amount of proteins (40 g) was separated by electrophoresis in a 10% or a 15% polyacrylamide gel, transferred to a nitrocellulose
membrane, and immunoreacted with the indicated antibody.
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in vivo model. As demonstrated in Figure 6, oral administra-
tion of prazosin caused a significant inhibition of tumor growth
without loss of body weight, indicating that prazosin under the
treatment dosages had negligible toxic effect (Figure 6).
Discussion
In the past decades, numerous prospects concerning chemo-
therapeutic approaches to prostate cancer have emerged.
Quinazoline-based a1-adrenoceptor antagonists are sug-
gested to display antitumor activity against prostate tumors.
The apoptotic and antiangiogenic effects of doxazosin and
terazosin have been widely explored [12–18]. However,
prazosin, which is also a quinazoline-based a1-blocker, does
not get equal attention in anticancer approach. One of the
reasons is that the plasma half-life of prazosin is shorter
(about 2–4 hours) than those of terazosin (12 hours) and
doxazosin (22 hours). However, the pharmacokinetic problem
can be resolved by improvement of the dosage form or by
multiple administrations to achieve the therapeutic plasma
concentration at which prazosin shows benefits in cancer
chemotherapy. In this study, prazosin showed superior inhib-
itory effect on proliferation in human androgen-dependent
and androgen-independent prostate cancer cells.
Checkpoints are the pathways that halt the progression
of cell cycle in response to cellular stress. The targets on
checkpoint pathways are potential anticancer strategies be-
cause abrogation of checkpoint function drives tumor cells
toward apoptosis and enhances the efficacy of oncotherapy
[2,8,24]. The regulation of cell-cycle progression by prazosin
is distinct from that by doxazosin. Prazosin induced G2 check-
point arrest before apoptosis, whereas doxazosin did not
cause any checkpoint arrest of the cell cycle. Several cellular
stresses may trigger checkpoint pathways, leading to cell-
cycle arrest at G2 phase. DNA damage is one of the feasible
stimuli [20,21,25]. Comet assay provided evidence that pra-
zosin induced DNA damage stress, triggering the activation of
ATM/ATR checkpoint pathways. One important issue is to
identify signaling cascades during DNA damage and G2
checkpoint arrest. The cyclin B/Cdk1 complex activity is a
candidate factor because it regulates cell-cycle progression
fromG2 to M phase [19–21,25]. It has been well identified that
Cdk1 phosphorylation at Thr161 and Tyr15 may oppositely
regulate its activity. The phosphorylation at Thr161 (mainly by
Cdk-activating kinase) is required for Cdk1 activation, where-
as the phosphorylation at Tyr15 (mainly by Wee-1 kinase)
inhibits Cdk1 activity [19]. Recently, it has been suggested that
Wee-1 plays a crucial role in keeping Cdk1 inactivation andG2
checkpoint arrest in prostate cancer cells [26]. The present
work showed that prazosin induced Cdk1 phosphorylation at
Tyr15 and downregulated cyclin B1 expression level, support-
ing that Cdk1 activity is inhibited by prazosin during the G2
arrest of the cell cycle.
The regulation of Cdc25c phosphatase on Cdk1 activity
has been explored. The nuclear-active Cdc25c phosphatase
can remove the inhibitory phosphorylation of Cdk1 at Tyr15
and can activate Cdk1 activity [19–21,27]. Chk2 and Chk1
are downstream effector kinases of ATM and ATR, respec-
tively. In response to DNA damage, activated Chk2 and Chk1
can phosphorylate Cdc25c at Ser216 and trigger its associ-
ation with 14-3-3 protein, leading to cytoplasmic sequestra-
tion of this phosphatase [20,21]. Prazosin induced a similar
pathway, including Cdc25c phosphorylation at Ser216 and
its subsequent nuclear export. The evidence may explain
Figure 4. Effect of prazosin on DNA damage stress in PC-3 cells. (A) Cells were treated with the indicated agent for 18 hours. Then the cells were fixed and stained
with PI to analyze DNA content by FACScan flow cytometric analysis. Data are expressed as the mean ± SEM of three independent determinations. (B) Comet
assay was employed to examine the integrity of chromosome DNA on treatment with prazosin (1 hour). Etoposide (50 M) was included as a positive control. One
hundred cells were scored to calculate the overall percentage of Comet tail –positive cells. Data are expressed as the mean ± SEM of three independent
experiments. *P < .05 and ***P < .001 compared with controls.
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Figure 5. Effect of prazosin on the expression of several proteins in PC-3 cells. (A–D) Cells were incubated in the absence or in the presence of prazosin (30 M)
for the indicated times. Then the cells were harvested and lysed for the detection of protein expression with the antibody by Western blot analysis. For Western blot
analysis, the amount of proteins (40 g) was separated by electrophoresis in a 10% or a 15% polyacrylamide gel, transferred to a nitrocellulose membrane, and
immunoreacted with the indicated antibody.
Figure 6. In vivo antitumor study against PC-3 cells. The nude mice were subcutaneously injected with PC-3 cells (107 cell/mouse). The tumors were measured
every 2 to 3 days. When the tumors had reached a volume of 100 to 140 mm3, the mice were divided into three groups (n = 7), and vehicle (0.5% CMC) or prazosin
(3 and 10 mg/kg) was given orally every day. Tumor volume was measured every 2 to 3 days.
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prazosin-induced increase in Cdk1 phosphorylation at Tyr15
and the inactivation of this kinase.
There are numerous lines of evidence suggesting that
mitochondria-mediated pathways contribute to the apoptosis
caused by tubulin-binding agents, topoisomerase poisons,
and some other apoptotic stimuli [28–31]. Bcl-2 family pro-
tein members always play central roles in the determination
of mitochondrial membrane permeability and cell survival.
Mcl-1 cleavage occurring after Asp127 and Asp157 may gen-
erate four products of 24, 19, 17, and 12 kDa [32,33]. Bad and
Bid, two proapoptotic Bcl-2 family members, can be cleaved
into a 13-kDa and/or a 15-kDa truncated protein by caspase-3
and caspase-8, respectively [34,35]. In this study, prazosin
induced the cleavage of Mcl-1, Bad, and Bid associated with
the formation of truncated fragments in PC-3 cells. These
effects occurred after G2 checkpoint arrest but correlated
well with the activation of caspases. The data suggest that
mitochondria-mediated pathways may play a central role in
prazosin-induced apoptotic mechanism in PC-3 cells.
The nude mice xenograft model was used to examine
the in vivo antitumor potential of prazosin. The oral admin-
istration of prazosin caused a significant inhibition of tumor
growth, revealing the in vivo efficacy of this drug. However,
prazosin only induced a partial remission of tumor mass.
The short plasma half-life might be one of the possibilities.
Terazosin and doxazosin are two quinazoline-based related
drugs with longer plasma half-lives. Nevertheless, in vivo
a1-adrenoceptor blocking efficacy, but not antitumor activity,
is improved by these two analogues. It indicates that not
only the quinazoline structure but also some other func-
tional groups of prazosin structure are necessary for the
antitumor purpose. Because the effective antitumor concen-
tration of prazosin is high, one issue would be that the ther-
apeutic concentration may be largely elevated. The proposal
to combine therapy with radiation treatment may be per-
formed to reduce prazosin levels. Moreover, the structure
design based on prazosin may be another proposal. The
discovery of new quinazoline-based chemical entities is
ongoing [36].
In conclusion, the data suggest that prazosin is a potential
anticancer agent that induces apoptotic signaling cascades
in a sequential manner. The exposure of PC-3 cells to
prazosin induces DNA damage stress and activation of
ATM/ATR, leading to an increase in Cdc25c phosphorylation
at Ser216 and the subsequent nuclear export of this phos-
phatase. Because of the absence of nuclear Cdc25c, a
substantial increase in Cdk1 phosphorylation at Tyr15 results
in the inactivation of Cdk1 and G2 checkpoint arrest. Subse-
quently, mitochondria-mediated pathways are triggered by
the cleavage of the Bcl-2 family of proteins. Finally, caspase
cascades are activated to execute apoptotic cell death in
response to prazosin action.
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